Drug intelligence / Profile preview

Tamarixetin

Development stage: Unknown
Modality: Small Molecules
Administration: Intraperitoneal (for Experimental Studies), Oral (potential)

Overview

Tamarixetin is a naturally occurring flavonoid derived from quercetin. It exhibits various biological activities, including anti-inflammatory, antioxidant, and anticancer properties. Tamarixetin has shown potential in treating conditions such as ischemic stroke, colorectal cancer, and liver injury. It acts by inhibiting pathways like the NLRP3 inflammasome and modulating signaling pathways such as NF-κB and WNT3A/β-catenin. Tamarixetin also protects chondrocytes from IL-1β-induced cellular stress and has been explored for its chondroprotective effects against osteoarthritis.

Other names: Chiosmethin4'-Methoxyquercetin

Targets

NF-κBNOX2 (NADPH oxidase 2)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on Tamarixetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tamarixetin.

Explore the full profile